The Biologics Paradigm: Wharton's Jelly Mesenchymal Exosomes as a Section 351(a) Drug vs. the Section 361 HCT/P pathway
Author: Andrew J. Hillman (ORCID 0009-0001-5396-321X)
Published: 2026, Zenodo
DOI: 10.5281/zenodo.21142612
License: CC BY 4.0
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. This paper describes published scientific literature. It does not describe an available treatment.
Read the full paper at its permanent record: doi.org/10.5281/zenodo.21142612.